Humberto Hernandez

Dr. Humberto Hernandez


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2022 in GeroScience
Verified
Journal Article
Closed access
PDF file
CTClaudia M. Trujillo-Vargas
Claudia M. Trujillo-Vargas
KMKelsey E. Mauk
Kelsey E. Mauk
HHHumberto Hernandez
Humberto Hernandez
RSRodrigo G. de Souza
Rodrigo G. de Souza
ZYZhiyuan Yu
Zhiyuan Yu
Cintia De PaivaCintia De Paiva
Cintia De Paiva

Verified
Journal Article
Open access
PDF file
CTClaudia Trujillo
Claudia Trujillo
SKShallu Kutlehria
Shallu Kutlehria
HHHumberto Hernandez
Humberto Hernandez
RSRodrigo G. de Souza
Rodrigo G. de Souza
ALAndrea Lee
Andrea Lee
Cintia De PaivaCintia De Paiva
Cintia De Paiva
Dry eye disease (DED), one of the most prevalent conditions among the elderly, is a chronic inflammatory disorder that disrupts tear film stability and causes ocular surface damage. Aged C57BL/6J mice spontaneously develop DED. Rapamycin is a potent immunosuppressant that prolongs the lifespan of several species. Here, we compared the effects of daily instillation of eyedrops containing rapamycin or empty micelles for three months on the aged mice. Tear cytokine/chemokine profile showed a pronounced increase in vascular endothelial cell growth factor-A (VEGF-A) and a trend towards decreased concentration of Interferon gamma (IFN)-γ in rapamycin-treated groups. A significant decrease in inflammatory markers in the lacrimal gland was also evident (IFN-γ, IL-12, CIITA and Ctss); this was accompanied by slightly diminished Unc-51 Like Autophagy Activating Kinase 1 (ULK1) transcripts. In the lacrimal gland and draining lymph nodes, we also observed a significant increase in the CD45+CD4+Foxp3+ cells in the rapamycin-treated mice. More importantly, rapamycin eyedrops increased conjunctival goblet cell density and area compared to the empty micelles. Taken together, evidence from these studies indicates that topical rapamycin has therapeutic efficacy for age-associated ocular surface inflammation and goblet cell loss and opens the venue for new investigations on its role in the aging process of the eye.